Tekla Life Sciences Investors
HQLNYSEFinancial Services● Active
$16.92
$-0.35(-2.03%)
Market Cap$514503360
P/E Ratio—
52W High$18.46
52W Low$12.34
Tekla Life Sciences Investors (HQL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HQL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2025Report Date: Jun 24, 2025EPS Actual
-$1.64
Revenue
$0.02B
Fiscal Period
Q2 FY2025
FY ends December
Report Date
Jun 24, 2025
After Market Close
HQL reports quarterly as a NYSE-listed Asset Management company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2025 | Jun 24, 2025 | — | -$1.64 | — | $0.02B | — | — |
| — Q4 FY2024 | Dec 9, 2024 | — | $1.22 | — | $0.00B | — | — |
| — Q3 FY2024 | Aug 6, 2024 | — | $1.84 | — | $0.00B | — | — |
| — Q4 FY2023 | Dec 11, 2023 | — | -$0.43 | — | $0.03B | — | — |
| — Q1 FY2023 | Mar 31, 2023 | — | $1.29 | — | $0.00B | — | — |
| — Q3 FY2022 | Sep 30, 2022 | — | -$1.10 | — | $0.02B | — | — |
| — Q1 FY2022 | Mar 31, 2022 | — | -$3.03 | — | $0.01B | — | — |
| — Q3 FY2021 | Sep 30, 2021 | — | $1.34 | — | $0.02B | — | — |
Q2 FY2025
Jun 24, 2025
EPS Actual
-$1.64
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q4 FY2024
Dec 9, 2024
EPS Actual
$1.22
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Aug 6, 2024
EPS Actual
$1.84
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2023
Dec 11, 2023
EPS Actual
-$0.43
EPS Est.
—
EPS Surpr.
—
Revenue
$0.03B
Q1 FY2023
Mar 31, 2023
EPS Actual
$1.29
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2022
Sep 30, 2022
EPS Actual
-$1.10
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q1 FY2022
Mar 31, 2022
EPS Actual
-$3.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q3 FY2021
Sep 30, 2021
EPS Actual
$1.34
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
No analyst estimates available for HQL.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2025 | Jun 24, 2025 | — | $12.47 | $12.79 | +2.57% |
| — Q4 FY2024 | Dec 9, 2024 | — | $14.28 | $14.32 | +0.28% |
| — Q3 FY2024 | Aug 6, 2024 | — | $14.64 | $14.91 | +1.84% |
| — Q4 FY2023 | Dec 11, 2023 | — | $12.44 | $12.49 | +0.40% |
| — Q1 FY2023 | Mar 31, 2023 | — | $13.79 | $13.93 | +1.02% |
| — Q3 FY2022 | Sep 30, 2022 | — | $13.70 | $13.66 | -0.29% |
| — Q1 FY2022 | Mar 31, 2022 | — | $16.45 | $16.54 | +0.55% |
| — Q3 FY2021 | Sep 30, 2021 | — | $20.75 | $20.80 | +0.24% |
Q2 FY2025+2.57%
Report Date
Jun 24, 2025
EPS Beat/Miss
—
Price Before
$12.47
Price After
$12.79
Q4 FY2024+0.28%
Report Date
Dec 9, 2024
EPS Beat/Miss
—
Price Before
$14.28
Price After
$14.32
Q3 FY2024+1.84%
Report Date
Aug 6, 2024
EPS Beat/Miss
—
Price Before
$14.64
Price After
$14.91
Q4 FY2023+0.40%
Report Date
Dec 11, 2023
EPS Beat/Miss
—
Price Before
$12.44
Price After
$12.49
Q1 FY2023+1.02%
Report Date
Mar 31, 2023
EPS Beat/Miss
—
Price Before
$13.79
Price After
$13.93
Q3 FY2022-0.29%
Report Date
Sep 30, 2022
EPS Beat/Miss
—
Price Before
$13.70
Price After
$13.66
Q1 FY2022+0.55%
Report Date
Mar 31, 2022
EPS Beat/Miss
—
Price Before
$16.45
Price After
$16.54
Q3 FY2021+0.24%
Report Date
Sep 30, 2021
EPS Beat/Miss
—
Price Before
$20.75
Price After
$20.80
Beat Rate0 / 8 quarters
Largest Move+2.57% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HQL ends December
Tekla Life Sciences Investors (HQL) most recently reported earnings on June 24, 2025 for Q2 FY2025, posting EPS of $-1.64 (in line with the analyst consensus of —). The next HQL earnings date is expected around September 1, 2026.
Each quarter, investors track HQL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HQL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HQL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HQL earnings · 4 questionsTekla Life Sciences Investors's next earnings report is expected around September 1, 2026. HQL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HQL historically reports after market close (AMC).
HQL earnings datewhen is HQL earningsHQL next earnings datewhen does HQL report earningsHQL earnings calendar
▸ Source: FMP · Tekla Life Sciences Investors SEC filings · US GAAP · Tekla Life Sciences Investors SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026